Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

• Published in: The Egyptian heart journal Vol. 75; no. 1; p. 28
• Main Authors: Jalalian, Rozita, Bagheri, Babak, Yazdani Charati, Jamshid, Khalaghi, Shahrnaz, Iranian, Mohammadreza, Mohammadi, Mahsa
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 15.04.2023; Springer; Springer Nature B.V; SpringerOpen
• Subjects: Angioplasty; Cardiology; Care and treatment; Eptifibatide; Heart attack; Heart attacks; Investigations; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Primary percutaneous coronary intervention (PPCI); ST-segment elevation myocardial infarction (STEMI); Tirofiban; Transluminal angioplasty; Primary percutaneous coronary intervention (PPCI); ST-segment elevation myocardial infarction (STEMI); Eptifibatide
• ISSN: 2090-911X; 1110-2608; 2090-911X
• DOI: 10.1186/s43044-023-00355-4

Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group ( n  = 147) received a maintenance dose of intravenous Eptifibatide (infusion of 2 μg/kg/min) and the other group ( n  = 117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3 months after the start of treatment in terms of predicted outcomes. Results The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%; P value: 0.286). Also, investigations showed that the rate of re-infarction ( P value: 0.024) and target lesion revascularization ( P value: 0.003) was significantly lower in the group that received Eptifibatide infusion. Conclusions Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events .